Skip to main content
Premium Trial:

Request an Annual Quote

People: Robert Saltmarsh, Nick Venuto

Premium
Robert Saltmarsh, the current vice president and chief financial officer at Nanogen, will retire from his position at the end of February 2008, the firm said last week. Saltmarsh will continue to consult with Nanogen through the end of next year as needed.
 
Nick Venuto, currently the firm's executive director of finance, has been named as Saltmarsh's successor. Venuto has been responsible for financial operations and reporting for the last four years.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.